Selatogrel and Other P2Y12 Inhibitors' Putative Off-Target Effects

Affiliations

¹ Cardiocentro Ticino Institute and Università della Svizzera Italiana (USI), Lugano, Switzerland.
² University of Sheffield, Sheffield, United Kingdom.
³ University Hospitals Leuven, Leuven, Belgium; and.
⁴ Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Comment

Marco Valgimigli et al. J Cardiovasc Pharmacol. 2022.

. 2022 Feb 1;79(2):153-154.

doi: 10.1097/FJC.0000000000001135.

¹ Cardiocentro Ticino Institute and Università della Svizzera Italiana (USI), Lugano, Switzerland.
² University of Sheffield, Sheffield, United Kingdom.
³ University Hospitals Leuven, Leuven, Belgium; and.
⁴ Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

No abstract available

Comment on

Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
Beavers CJ, Effoe SA, Dobesh PP. Beavers CJ, et al. J Cardiovasc Pharmacol. 2022 Feb 1;79(2):161-167. doi: 10.1097/FJC.0000000000001079. J Cardiovasc Pharmacol. 2022. PMID: 34132688

1. Beavers CJ, Effoe SA, Dobesh PP. Selatogrel: a novel subcutaneous P2Y: 12: inhibitor. J Cardiovasc Pharmacol. 2021 [epub ahead of print]. doi: 10.1097/FJC.0000000000001079. - DOI
1. Storey RF, Gurbel PA, ten Berg J, et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J. 2020;41:3132–3140.
1. Sinnaeve P, Fahrni G, Schelfaut D, et al. Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. J Am Coll Cardiol. 2020;75:2588–2597.
1. Baumann M, Lack B, Guillaumat I, et al. The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration. Platelets. 2021;1–10. doi: 10.1080/09537104.2020.1869711. [epub ahead of print]. - DOI
1. Parker WA, Bhatt DL, Prats J, et al. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb Haemost. 2017;117:1093–1100.